News
AMRN
15.46
-1.72%
-0.27
Amarin: The Market Is Pricing A 55% Chance Of A Sale That Isn't Coming
Seeking Alpha · 10h ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11h ago
Weekly Report: what happened at AMRN last week (0629-0703)?
Weekly Report · 1d ago
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
NASDAQ · 6d ago
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL
Benzinga · 06/30 20:18
Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape
Barchart · 06/30 15:15
Weekly Report: what happened at AMRN last week (0622-0626)?
Weekly Report · 06/29 09:22
Weekly Report: what happened at AMRN last week (0615-0619)?
Weekly Report · 06/22 09:25
Weekly Report: what happened at AMRN last week (0608-0612)?
Weekly Report · 06/15 09:25
Palisade Bio adds Robert Baltera, Jordan Zwick to board of directors
PUBT · 06/11 12:45
Weekly Report: what happened at AMRN last week (0601-0605)?
Weekly Report · 06/08 09:24
U.S. Supreme Court Ends Amarin Patent Fight, Hikma Prevails
NASDAQ · 06/05 05:34
US Supreme Court ends Amarin patent suit against Hikma over generic Vascepa
PUBT · 06/04 19:33
Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics
Seeking Alpha · 06/04 17:46
U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By Amarin
Benzinga · 06/04 14:10
U.S. SUPREME COURT RULES IN FAVOR OF GENERIC DRUGMAKER HIKMA IN 'SKINNY LABEL' PATENT DISPUTE OVER AMARIN HEART DRUG VASCEPA
Reuters · 06/04 14:01
Weekly Report: what happened at AMRN last week (0525-0529)?
Weekly Report · 06/01 09:25
Amarin Presents RW-ApoB As Risk Identifier For Cardiovascular Disease Based On REDUCE-IT Data
NASDAQ · 05/28 07:30
Amarin post hoc REDUCE-IT analysis says risk-weighted apoB better flags residual CV risk in statin-treated patients
PUBT · 05/27 12:04
Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk
Benzinga · 05/27 12:03
More
Webull provides a variety of real-time AMRN stock news. You can receive the latest news about Amarin through multiple platforms. This information may help you make smarter investment decisions.
About AMRN
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.